ClinicalTrials.gg
RecruitingNCT05655845Updated Aug 23, 2023

Risk Factors for Bowel Dysfunction at Preschool and Early Childhood Age in Children With Hirschsprung Disease

An observational study in Bowel Dysfunction, Hirschsprung Disease and Risk Factor, sponsored by Weibing Tang. Recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.

Primary conditionHirschsprung DiseaseRegistry: Intestinal DiseasesReclassifiedWhy we changed it
Registry
Intestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hirschsprung Disease
Why
  1. The study's listed conditions name Hirschsprung Disease, a narrower term within Intestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Weibing Tang · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
300
Ages
3 Years and older
Sex
All
01

Study summary

Bowel dysfunction has been proven as the most common complication after pull-through(PT) of Hirschsprung disease(HD) ,which may persist to adulthood and lead to social problems.The reason of bowel dysfunction is complicated and the risk factors were not defined.

Read the detailed description

Hirschsprung disease (HD) is a distinctive congenital disease with the absence of ganglion cells in the distal intestine leads to distal bowel obstruction and defecation disorders. HD is a rare disease, with a reported incidence of 1:5,000, requiring proper surgical treatment for the maintenance of normal or near-normal bowel movement.To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair, and a pull-through with or without laparoscopy was the most common procedure for correction of HD,which may have faster recovery and less rate of complication compared to other surgical approaches.The short or long-term outcomes of HD have been deeply assessed in the past few years,and bowel dysfunction,consist of soling, incontinence and constipation, had been proven as the most common complication,which may be a ongoing issue and lead to social problems,which should not be ignored. Otherwise,there were many reports proved that poor bowel function in preschool and early childhood may lead to social problems and depression in adolescence or adult.Many factors may lead to bowel dysfunction in HD, including length of aganglionic segement,anastomotic leakage or redo-PT,unsuitable timing of surgery,etc.Thus,the present study was designed to seek the risk factors for bowel dysfunction of HD,which is meaningful to maintain or improve the bowel function in preschool and early childhood.

02

Conditions studied

  • Bowel Dysfunction
  • Hirschsprung Disease
  • Risk Factor
  • Incontinence
  • Constipation

Browse trials for

Keywords

  • Hirschsprung Disease
  • Bowel function
  • associated factors
03

In context

Hirschsprung Disease Reclassified

63 studies on the registry are indexed under Hirschsprung Disease; 24 are open to participants now.

This study's planned enrollment of 300 is close to the median of 300 across 31 observational studies indexed under Hirschsprung Disease.

Browse Hirschsprung Disease studies →

Lead sponsor

Weibing Tang is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Compared within Hirschsprung Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical dignosis with Hirschsprung disease
  2. completed the toilet training

Exclusion criteria

Exclusion Criteria:

  1. redo-pull-through,
  2. Down syndrome or other co-morbidities that impaired functional outcomes
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dysfunction group

    Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score \< 17 were considered to have bowel dysfunction.

    Other: bowel function score(BFS) questionnaire survey

  • near-normal group

    Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score \> 17 were considered to have normal bowel habits.

    Other: bowel function score(BFS) questionnaire survey

Interventions

  • Otherbowel function score(BFS) questionnaire survey

    A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .

06

What researchers measure

Primary outcomes

  1. bowel function score

    Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score \> 17 were considered to have normal bowel habits. 7 items were in BFS,including ability to hold back defecation,feels/reports the urge to defecate,frequency of defecation,soiling,accidents,constipation.

    Time frame: through study completion, an average of 5 year

  2. Clavien-Dindo classifification of surgical complications

    Clavien-Dindo is an objective grading system, which is used for grading postoperative complications in a reproduceable manner.It consists of five grades ranging from any deviation from a normal postoperative course (Grade I) to death (Grade V)

    Time frame: through study completion, an average of 5 year

  3. Hirschsprung disease associated enterocolitis(HAEC)

    The guidelines for the diagnosis and management of HAEC were defined by the American Pediatric Surgical Association in 2017. There are three types of HAEC defined by severity: possible HAEC \[grade I\]; definite HAEC \[gradeⅡ\]; and severe HAEC \[grade Ⅲ\].

    Time frame: through study completion, an average of 5 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — All data generated or analyzed during this study are available from the corresponding authors upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Aug 2023, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 19, 2022
StartActual
Aug 20, 2022
Primary completionEst.
Aug 30, 2023
CompletionEst.
Aug 30, 2023
Last update
Aug 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05655845
Lead sponsor
Weibing Tang
Responsible party
Weibing Tang (Clinical Professor, Nanjing Children's Hospital) — Sponsor-investigator
First posted
Dec 19, 2022
Start date
Aug 20, 2022
Primary completion
Aug 30, 2023 (estimated)
Completion
Aug 30, 2023 (estimated)
Last update
Aug 23, 2023

Study contacts

Changgui Lu, Dr
Contact
luchanggui1984@163.com
13770848448
Weibing Tang, Dr
study director · Children's Hospital of Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion